Company Profile

Cellivery Therapeutics, Inc. is a Korea-based company principally engaged in the research and development of medicines and biotherapeutics. The Company develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The Company research and develop therapeutic drug candidates such as Parkinsonâs disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Employees

Sector

Biotechnology & Medical Research

Calendar

03-19 - Q4 2025 Earnings Release (Projected)

More about the company

23-04-05	Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index	CI
21-11-16	Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion.	CI
21-11-15	Cellivery Therapeutics, Inc. agree to acquire Ajin Clean Co., Ltd. for KRW 14.9 billion.	CI
21-10-14	Cellivery Therapeutics, Inc. announced that it has received KRW 38.9997004 billion in funding	CI
21-09-30	Cellivery Therapeutics to Raise Nearly $17 Million Through Stock Sale	MT
21-09-29	Cellivery Therapeutics, Inc. announced that it expects to receive KRW 38.9997004 billion in funding	CI
21-09-23	Cellivery Therapeutics to Raise $13 Million from Stock Offering	MT
20-08-18	Cellivery Therapeutics, Inc. announced that it has received KRW 43.9988081 billion in funding from a group of investors	CI
20-08-05	Cellivery Therapeutics, Inc. announced that it expects to receive KRW 43.9988081 billion in funding from a group of investors	CI
19-03-18	Cellivery Therapeutics, Inc.(KOSDAQ:A268600) added to S&P Global BMI Index	CI
18-11-08	Cellivery Therapeutics, Inc has completed an IPO in the amount of KRW 28.5 billion.	CI
18-07-11	Cellivery Therapeutics, Inc has filed an IPO.	CI

Manager	Title	Age	Since
Dae-Woong Cho CEO	Chief Executive Officer	57	2014-08-27
Sun-Hong Kwon PRN	Corporate Officer/Principal	52	2021-03-28
Byung-Hwa Lee AUD	Comptroller/Controller/Auditor	62	2019-03-21

Director	Title	Age	Since
Dae-Woong Cho BRD	Director/Board Member	57	2014-08-27
Sun-Hong Kwon BRD	Director/Board Member	52	2021-03-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CELLIVERY THERAPEUTICS, INC.	-30.43%	-75.38%	-	-	405K
ARGENX SE	-0.49%	0.00%	+8.21%	+89.09%	49.52B
WUXI APPTEC CO., LTD.	+0.71%	+6.24%	+95.76%	+14.62%	44.32B
INSMED INCORPORATED	+1.86%	-7.90%	+122.78%	+747.65%	33.97B
BIONTECH SE	+2.24%	+8.37%	-4.04%	-24.44%	26.62B
GENMAB A/S	+0.97%	+0.14%	+43.23%	-21.74%	20.71B
WUXI BIOLOGICS (CAYMAN) INC.	-0.60%	+9.17%	+128.36%	-45.21%	21.22B
AKESO, INC.	-0.74%	-5.62%	+114.16%	+148.46%	14.4B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.72%	+0.98%	+192.83%	-	14.07B
SUMMIT THERAPEUTICS INC.	-0.55%	-12.32%	-5.14%	+275.93%	13.32B
Average	-2.62%	+0.45%	+77.35%	+148.04%	26.46B
Weighted average by Cap.	+0.55%	+1.14%	+69.79%	+152.67%

Cellivery Therapeutics, Inc. Stock

Equities

A268600

KR7268600004

Biotechnology & Medical Research

Chart: Cellivery Therapeutics, Inc.

Latest news: Cellivery Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Cellivery Therapeutics, Inc.

Bio Therapeutic Drugs

Company Profile